PCSK9: a target for hypercholesterolaemia in nephrotic syndrome

被引：6
|
作者：
Alan W. J. Morris
机构：
来源：
Nature Reviews Nephrology | 2016年 / 12卷 / 9期
关键词：
D O I：
10.1038/nrneph.2016.111
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：510 / 510
相关论文
共 50 条
  • [11] PCSK9 is a new target of FXR
    Langhi, C.
    Arnaud, L.
    Jarnoux, Al
    Krempf, M.
    Costet, P.
    Cariou, B.
    DIABETES & METABOLISM, 2007, 33 : S39 - S39
  • [12] PCSK9 as a Therapeutic Target in Atherosclerosis
    Ali J. Marian
    Current Atherosclerosis Reports, 2010, 12 (3) : 151 - 154
  • [13] PCSK9 as a therapeutic target of dyslipidemia
    Seidah, Nabil G.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (01) : 19 - 28
  • [14] PCSK9 and a new target of FXR
    Langhi, C.
    Arnaud, L.
    Jarnoux, A. L.
    Krempf, M.
    Costet, P.
    Cariou, B.
    DIABETES & METABOLISM, 2007, 33 : S31 - S31
  • [15] PCSK9 inhibitors for hypercholesterolaemia New drugs, old problems
    McGettigan, Patricia
    Ferner, Robin E.
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 356
  • [16] Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
    Jin, Kyubok
    Park, Bong-Soo
    Kim, Yang-Wook
    Vaziri, Nosratola D.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (04) : 584 - 589
  • [17] Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
    Awanami, Yuki
    Fukuda, Makoto
    Nonaka, Yasunori
    Takashima, Tsuyoshi
    Matsumoto, Keiichiro
    Yamasaki, Masatora
    Miyazono, Motoaki
    Ikeda, Yuji
    BMC NEPHROLOGY, 2017, 18
  • [18] Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
    Yuki Awanami
    Makoto Fukuda
    Yasunori Nonaka
    Tsuyoshi Takashima
    Keiichiro Matsumoto
    Masatora Yamasaki
    Motoaki Miyazono
    Yuji Ikeda
    BMC Nephrology, 18
  • [19] New perspectives in the treatment of hypercholesterolaemia since the availability of PCSK9 inhibitors
    Pinto, X.
    Sarasa, I
    HIPERTENSION Y RIESGO VASCULAR, 2019, 36 (04): : 213 - 220
  • [20] PCSK9 inhibitor reduces need for lipoprotein apheresis in familial hypercholesterolaemia
    Gregory B. Lim
    Nature Reviews Cardiology, 2016, 13 (11) : 634 - 634
12345